Letter by Lozano et al Regarding Article, “Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We have read with interest the article written by Motovska et al1 and the editorial of Bonaca2 about the direct comparison between prasugrel and ticagrelor in primary angioplasty. The introduction of the new antiplatelet agents was based on the pivotal studies in which both agents were tested against clopidogrel. The present study tries to find out if one of these agents may be superior to the other, but the results show a lack of difference with that sample size.
The advantages of clopidogrel over ticlopidine were simple to prove because it was sufficient with similar clinical results without the dependence of a twice-a-day administration and to avoid the possibility of …